8
original article
Dose-Dependency of Toxic Signs
and Outcomes of Paraoxon Poisoning in Rats
Žana M. Maksimović1,*, Ranko Škrbić1,2, Miloš P. Stojiljković1,2
ABSTRACT
Organophosphorus compounds induce irreversible inhibition of acetylcholinesterase, which then produces clinically manifested
muscarinic, nicotinic and central effects. The aim of the study was to analyse the clinical signs of acute paraoxon poisoning in rats and to
determine the relationship between the intensity of signs of poisoning and the dose of paraoxon and/or the outcome of poisoning in rats.
Animals were treated with either saline or atropine (10 mg/kg intramuscularly). The median subcutaneous lethal dose (LD50) of paraoxon
was 0.33 mg/kg and protective ratio of atropine was 2.73. The presence and intensity of signs of poisoning in rats (dyspnoea, lacrimation,
exophthalmos, fasciculations, tremor, ataxia, seizures, piloerection, stereotypic movements) were observed and recorded for 4 h after
the injection of paraoxon. Intensity of these toxic phenomena was evaluated as: 0 – absent, 1 – mild/moderate, 2 – severe. Fasciculations,
seizures and tremor were more intense at higher doses of paraoxon and in non-survivors. In unprotected rats piloerection occurred more
often and was more intense at higher doses of paraoxon as well as in non-survivors. In atropine-protected rats, piloerection did not
correlate with paraoxon dose or outcome of poisoning. The intensity of fasciculations and seizures were very strong prognostic parameters
of the poisoning severity.
KEYWORDS
organophosphate; insecticide; paraoxon; poisoning; acetylcholinesterase inhibitor; atropine
A U T H O R A F F I L I AT I O N S
Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, Banja Luka, the Republic of Srpska, Bosnia and Herzegovina
2
Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, Banja Luka,
the Republic of Srpska, Bosnia and Herzegovina
* Corresponding author: Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, Banja Luka, the Republic
of Srpska, Bosnia and Herzegovina; e-mail: zana.maksimovic@med.unibl.org
1
Received: 9 July 2021
Accepted: 23 February 2022
Published online: 29 June 2022
Acta Medica (Hradec Králové) 2022; 65(1): 8–17
https://doi.org/10.14712/18059694.2022.10
© 2022 The Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
Paraoxon Toxicity Signs Related to Dose and Outcome
INTRODUCTION
Acetylcholinesterase (AChE, EC 3.1.1.7) is a very potent enzyme whose role is to break down acetylcholine (ACh) in
the synaptic cleft (1, 2). Inhibition of AChE results in the
accumulation of ACh and excessive stimulation of cholinergic receptors. AChE inhibitors (AChEI) can be reversible
(carbamate compounds) and irreversible (organophosphorus compounds – OPCs) (3–5). OPCs form a stable covalent bond with AChE, which is not spontaneously hydrolysed (6). They are divided into two major groups, nerve
agents (tabun, sarin, soman, VX) (7) and organophosphorus insecticides (OPI). Paraoxon (diethyl (4-nitrophenyl)
phosphate) is an active metabolite of the highly toxic OPI
parathion (8). Among the OPIs, paraoxon is very similar
to nerve agents, in terms of its median lethal dose (LD50),
profile of inhibition of cholinesterases and general toxicity (9).
Acute OPC poisoning manifests itself with muscarinic effects (bronchoconstriction, bronchorroea, bradycardia, hypotension, nausea, vomiting, increased motility of
bowels and bladder, miosis, hypersalivation, lacrimation),
nicotinic effects (tachycardia, hypertension, fibrillation,
fasciculations, skeletal muscle necrosis, mydriasis) and
CNS effects (tremor, convulsions, coma, respiratory depression) (10). Intermediate syndrome can occur after
1–4 days and, 1–2 weeks later, organophosphate-induced
delayed neuropathy (OPIDN) can be seen.
Treatment of OPC poisoning is based on a triple regimen: symptomatic anticholinergic therapy (atropine),
AChE reactivators (oximes) and anticonvulsants (mainly
diazepam) (11). Atropine as an antimuscarinic drug, alleviates the muscarinic effects of OPC poisoning, but has no
impact on the nicotinic ones. Oximes bind to OPC already
bound to AChE, which leads to the reactivation of AChE,
with variable affinity for different OPCs between oximes.
Diazepam inhibits the excitability of the neurons in the
CNS; by increasing the effect of GABA, it increases cAMP,
decreases the level of cGMP, leading to the cessation of
convulsions (11).
The aim of the study was to analyse the clinical signs
of acute paraoxon poisoning in rats and to determine
whether there is a relationship between the intensity of
toxicity signs and the dose of paraoxon and/or outcome
of poisoning.
MATERIAL AND METHODS
ANIMALS
The study was conducted in adult Wistar rats weighing
200–240 g, purchased from the Faculty of Natural Sciences and Mathematics, University of Banja Luka, the Republic of Srpska. The animals were given water and food
ad libitum, kept at a temperature of 20–22 °C, with a 12 h
cycle of light and darkness. The study was approved by the
Ethics Committee for the Protection and Welfare of Experimental Animals in Biomedical Research, Faculty of Medicine, University of Banja Luka (Decision No 18/1/20). The
animals were treated in accordance with the Guide for the
Care and Use of Laboratory Animals (12). The study was
9
conducted at the Centre for Biomedical Research, Faculty
of Medicine, University of Banja Luka.
CHEMICALS
Paraoxon was purchased from Sigma Aldrich, St Louis,
MO, USA. Paraoxon was dissolved in isopropyl alcohol up
to a concentration of 100 mg/mL and final dilution to the
desired concentration was made with saline (0.9% NaCl).
Atropine sulphate was dissolved in saline to a concentration of 10 mg/mL. The volumes of administered paraoxon
and atropine were 1 mL/kg. Paraoxon and atropine were
administered subcutaneously (sc) and intramuscularly
(im), respectively. Final dilutions were made immediately
before application.
STUDY DESIGN
The LD50 of paraoxon was determined by the “up and down”
method according to Litchfield and Wilcoxon (1949) (13).
In the first part of the experiment, then following doses
of paraoxon were administered: 0.2, 0.3, 0.35, 0.4 mg/kg
sc. One minute after paraoxon the saline (1 mL/kg, im)
was administered. In the second part of the experiment,
the following doses of paraoxon were administered: 0.6,
0.9 and 1.2 mg/kg sc. Atropine 10 mg/kg im was injected
1 minute after paraoxon application.
The presence and intensity of signs of paraoxon poisoning in animals were observed and recorded for 4 h.
The following signs have been observed: dyspnoea, lacrimation, exophthalmos, fasciculations, tremor, ataxia, seizures, piloerection, stereotypic movements. Their
presence and intensity were noted at the minutes: 5, 10,
15, 30, 60, 90, 120, 150, 180, 210 and 240 after paraoxon application. Intensity was evaluated as: 0 – absent, 1 – mild/
moderate, 2 – severe. Signs of poisoning were observed in
relation to the dose of paraoxon, as well as the outcome of
the poisoning (survival or death).
Tab. 1 Time of death from paraoxon administration depending on
paraoxon dose.
POX dose (mg/kg sc)
With
saline
With
atropine
Mean ± SD
95% CI
0.2
–
–
0.3
16.67 ± 7.51
−1.98–35.31
0.35
22.00 ± 3.61
18.67–25.33
0.4
18.09 ± 6.99
13.39–22.78
All
19.19 ± 6.19
16.37–22.01
0.6
–
–
0.9
14.00 ± 3.83
7.91–20.09
1.2
14.00 ± 4.24
7.25–20.75
All
Total
Time of death (minute)
14.00 ± 3.74
10.87–17.13
17.76 ± 6.04
15.46–20.06
SD: standard deviation; CI: confidence interval; POX: paraoxon;
Administered volumes of paraoxon, atropine and saline were 1 mL/kg;
Atropine at a dose of 10 mg/kg im was given 1 minute after paraoxon
application.
10
Žana M. Maksimović et al. Acta Medica (Hradec Králové)
STATISTICS
The LD50 and the PR were analysed by the method of Litchfield and Wilcoxon (1949) on Pharm/PCS statistical
software. Other analyses were performed on IBM SPPS
for Windows, Version 18.0. After the Kolmogorov-Smirnov test showed an unequal distribution of data, appropriate nonparametric tests were applied: Chi-square test (or
Fisher exact test) and Kruskal-Wallis test. Statistical significance level was set at p < 0.05.
RESULTS
The LD50 of paraoxon was 0.33 mg/kg sc (95% CI: 0.31–
0.36). The LD50 of paraoxon when atropine was administered was 0.91 mg/kg sc (95% CI: 0.67–1.25). Therefore, the
PR of atropine was 2.73. All deaths occurred during the
first hour of poisoning (Table 1).
CLINICAL SIGNS OF POISONING
1. Fasciculations
Frequency of fasciculations was not correlated with the
dose of paraoxon (Table 2).
In atropine-protected rats, fasciculations occurred
more often in non-survivors (p = 0.023) (Table 3).
Fasciculations occurred earlier and were more intense
at higher doses of paraoxon (Figure 1). Although the intensity of fasciculations were related to the dose of paraoxon
throughout the observed period, the difference was significant in the minutes 10, 15, 30, 210 and 240 (Kruskal-Wallis
test, p = 0.035, p = 0.045, p = 0.038, p = 0.014 and p = 0.034,
respectively).
Due to atropine protection, higher doses of paraoxon
could be administered. The intensity of fasciculations depending on paraoxon dose when atropine was administered is shown in Figure 2. Atropine did not influence the
Tab. 2 Frequency of signs of poisoning related to paraoxon dose.
Paraoxon + Saline
Sign
Paraoxon (mg/kg, sc)
Paraoxon + Atropine
Total
p*
83.33
85.71
83.33
100.00
100.00
100.00
0.00
33.33
Exophthalmos
83.33
Lacrimation
83.33
0.2
0.3
0.35
0.4
100.00
66.67
100.00
Seizures
66.67
75.00
Tremor
83.33
Fasciculations
Piloerection
Ataxia
Paraoxon (mg/kg, sc)
Total
p*
50.00
77.78
0.250
100.00
100.00
94.44
1.000
100.00
100.00
100.00
100.00
1.000
0.009
50.00
50.00
0.00
33.33
0.149
95.23
0.498
83.33
100.00
100.00
94.44
1.000
54.76
0.501
16.67
33.33
16.67
22.22
1.000
0.6
0.9
1.2
0.080
100.00
83.33
83.33
0.225
83.33
100.00
97.61
0.143
66.67
75.00
50.00
91.67
100.00
100.00
50.00
50.00
50.00
83.33
58.33
75.00
58.33
66.67
0.691
66.67
33.33
33.33
44.44
0.589
Stereotypy
100.00
66.67
83.33
41.67
69.05
0.044
66.67
0.00
50.00
38.89
0.095
Dyspnoea
33.33
33.33
25.00
16.67
26.19
0.862
50.00
50.00
33.33
44.44
1.000
* Chi-squared test (Fisher exact), bold: statistical significance. Values in the table are in percentages; sc: subcutaneously; im: intramuscularly; Administered
volumes of paraoxon, atropine and saline were 1 mL/kg; Atropine at a dose of 10 mg/kg im was given 1 minute after paraoxon application.
Tab. 3 Frequency of signs of poisoning related to poisoning outcome.
Paraoxon + Saline
Sign
Rat survived
Paraoxon + Atropine
Total
p*
Rat survived
Total
p*
100.00
77.78
0.023
90.00
100.00
94.44
1.000
1.000
100.00
100.00
100.00
1.000
0.002
40.00
25.00
33.33
0.638
1.000
90.00
100.00
94.44
1.000
54.76
0.062
20.00
25.00
22.22
1.000
61.90
66.67
0.744
70.00
12.50
44.44
0.025
85.71
52.23
69.05
0.043
60.00
12.50
38.89
0.066
28.57
23.81
26.19
1.000
60.00
25.00
44.44
0.239
Yes
No
Yes
No
Fasciculations
85.71
85.71
85.71
1.000
50.00
Seizures
66.67
100.00
83.33
0.009
Tremor
95.23
100.00
Piloerection
23.81
76.19
97.61
50.00
Exophthalmos
95.23
95.23
95.23
Lacrimation
71.43
38.10
Ataxia
71.43
Stereotypy
Dyspnoea
* Chi-squared test (Fisher exact), bold: statistical significance; Values in the table are in percentages; im: intramuscularly; Administered volumes
of paraoxon, atropine and saline were 1 mL/kg; Atropine at a dose of 10 mg/kg im was given 1 minute after paraoxon application.
Paraoxon Toxicity Signs Related to Dose and Outcome
Fig. 1 Intensity of fasciculations in rats depending on paraoxon dose.
* Kruskal-Wallis test, red colour: statistical significance; POX: paraoxon; sc: subcutaneously; Minute:
minutes 10, 15, 30, 120, 210 and 240 after paraoxon application.
Fig. 2 Intensity of fasciculations depending on paraoxon dose in rats protected with atropine.
* Kruskal-Wallis test, red colour: statistical significance; POX: paraoxon; sc: subcutaneously; Minute:
minutes 5, 10, 90, 120, 180 and 240 after paraoxon application; Atropine at a dose of 10 mg/kg im was
given 1 minute after paraoxon application.
Fig. 3 Intensity of fasciculations in relation to whether rat treated with paraoxon survived or not.
* Fisher exact test, red colour: statistical significance; Minute: minutes 5, 10, 15 and 30 after paraoxon application.
11
12
intensity of fasciculations. Fasciculations occurred earlier
and were more intense at higher doses of paraoxon. Although the intensity of fasciculations was related to the
dose of paraoxon throughout the observed period, the difference was significant in the minute 60 (data not shown),
90, 120 and 240 (Kruskal-Wallis test, p = 0.033, p = 0.048,
p = 0.048 and p = 0.044, respectively).
In unprotected rats intensity of fasciculations was in
correlation with the outcome of poisoning (higher intensity was in non-survivors) (Figure 3). In atropine-protected rats, fasciculation intensity did not correlate with the
outcome of poisoning.
2. Seizures
Frequency of seizures was not correlated with the dose
of paraoxon (Table 2), but seizures were more often in
non-survivors compared to survivors (Table 3). Seizures
Žana M. Maksimović et al. Acta Medica (Hradec Králové)
occurred earlier and were more intense at higher doses
of paraoxon (Figure 4). Although the intensities of seizures were related to the dose of paraoxon throughout
the observed period, the difference was significant only at
minutes 15, 180 and 210 (Kruskal-Wallis test, p = 0.002,
p = 0.024 and p = 0.015, respectively).
A clear relation between paraoxon dose and seizure intensity can be seen in atropine-protected rats (Figure 5).
Although the intensity of seizures was related to the dose
of paraoxon throughout the observed period, the difference was significant only at minutes 10, 15, 210 and 240
(Kruskal-Wallis test, p = 0.031, p = 0.014, p = 0.044 and
p = 0.011, respectively).
In unprotected rats the intensity of seizures was in correlation with the outcome of poisoning (higher intensity
was in non-survivors) (Figure 6). In atropine-protected
rats, the intensity of seizures did not correlate with the
outcome of poisoning.
Fig. 4 Intensity of seizures in rats depending on paraoxon dose.
* Kruskal-Wallis test, red colour: statistical significance; POX: paraoxon; sc: subcutaneously;
Minute: minutes 10, 15, 90, 180, 210 and 240 after paraoxon application.
Fig. 5 Intensity of seizures depending on paraoxon dose in rats protected by atropine.
* Kruskal-Wallis test, red colour: statistical significance; POX: paraoxon; sc: subcutaneously; Minute: minutes 10, 15, 90, 180,
210 and 240 after paraoxon application; Atropine at a dose of 10 mg/kg im was given 1 minute after paraoxon application.
Paraoxon Toxicity Signs Related to Dose and Outcome
13
Fig. 6 Intensity of seizures in relation to whether rat treated with paraoxon survived or not.
* Fisher exact test, red colour: statistical significance; Minute: minutes 5, 10, 15 and 30 after paraoxon application.
3. Tremor
Frequency of tremor was not correlated with the paraoxon dose (Table 2) or the outcome of poisoning (Table 3).
Tremor occurred earlier and was more intense at higher
doses of paraoxon (Figure 7). Although the intensity of
tremor was related to the dose of paraoxon throughout the
observed period, the difference was significant at minutes
10, 15 and 240 (Kruskal-Wallis test, p = 0.001, p = 0.002 and
p = 0.044, respectively).
In the atropine-protected rats, although a higher intensity of tremor was observed at higher doses of paraoxon,
the difference was not significant, except at minute 10
(χ2 = 9.88, p = 0.007) and 30 (χ2 = 6.00, p = 0.050).
In unprotected rats intensity of tremor was in correlation with the outcome of poisoning (higher intensity was
in non-survivors) (Figure 8). In atropine-protected rats,
the intensity of tremor did not correlate with the outcome
of poisoning.
4. Piloerection
Piloerection as a clinical sign of poisoning occurred early (within the first half hour of poisoning) and lasted for
a short time (Figure 9). Piloerection occurred more often
(Table 2) and was more intense at higher doses of paraoxon administered to unprotected rats. The difference
was significant at minutes 10 and 15 (Kruskal-Wallis test,
p = 0.052 and p = 0.012, respectively).
In atropine-protected rats, piloerection did not correlate with paraoxon dose.
In unprotected rats intensity of piloerection was in correlation with the outcome of poisoning. Piloerection was
Fig. 7 Intensity of tremor in rats depending on paraoxon dose.
* Kruskal-Wallis test, red colour: statistical significance; POX: paraoxon; sc: subcutaneously; Minute: minutes 10, 15, 30, 60
and 240 after paraoxon application.
14
Žana M. Maksimović et al. Acta Medica (Hradec Králové)
Fig. 8 Intensity of tremor in relation to whether rat treated with paraoxon survived or not.
* Fisher exact test, red colour: statistical significance; Minute: minutes 5, 10, 15 and 30 after paraoxon application.
Fig. 9 Intensity of piloerection in rats depending on paraoxon dose.
* Kruskal-Wallis test, red colour: statistical significance; POX: paraoxon; sc: subcutaneously;
Minute: minutes 5, 10, 15 and 30 after paraoxon application.
Fig. 10 Intensity of piloerection in relation to whether rat treated with paraoxon survived or not.
* Fisher exact test, red colour: statistical significance; Minute: minutes 5, 10, 15 and 30 after paraoxon application.
Paraoxon Toxicity Signs Related to Dose and Outcome
more often (Table 3) and of higher intensity in non-survivors (Figure 10). In atropine-protected rats, piloerection
did not correlate with the outcome of poisoning.
The intensity of stereotypical movements, exophthalmos, lacrimation, ataxia and dyspnoea was not related to
the dose of paraoxon or to the outcome of poisoning. The
above results are not shown. Of the listed signs, stereotypical movements were less often with higher doses of
paraoxon (p = 0.044) (Table 2). Related to poisoning outcome, ataxia (p = 0.025) was observed more often in survivors from the group of atropine-protected rats, while
stereotypical movements (p = 0.043) were observed more
often in survivors from the group of unprotected rats
(Table 3).
DISCUSSION
Due to its extreme toxicity, the World Health Organization (WHO) has classified parathion, parent compound
of paraoxon, as a class Ia (extremely hazardous) pesticide
(14). Due to its toxicity, it is banned in most developed
countries. Tabun, sarin, soman and VX represent OP compounds similar to parathion and paraoxon, with the same
mechanism of action (inhibition of acetylcholinesterase)
and their extreme toxicity classifies them as nerve agents.
Their production, stockpiling, weaponosing and use is
strictly prohibited by the 1993 Chemical Weapons Convention (CWC) (7). In undeveloped and developing countries,
OPI poisonings, both accidental and intentional, are common (15, 16). In Sri Lanka and China, pesticide poisoning is
the most common method of fatal self-harm (17).
The LD50 of paraoxon obtained in this study was
0.33 mg/kg sc, which corresponds with the results of other researchers (18). The PR of atropine was 2.73, which is
in accordance with the known publications (19). Atropine
is effective in blocking the effects of muscarinic but is
ineffective against the nicotinic signs of OPC poisoning
(20). This antimuscarinic drug is liposoluble and passes
the blood-brain barrier (21). Therefore, it to some extent,
antagonises the toxic effects of excessive cholinergic stimulation in the brain (22). It seems that a more lipophilic antimuscarinic drug would be more effective than atropine
(23). Krutak-Krol and Domino (24) found that the atropine
dose of 10 mg/kg im is optimal in experimental studies.
The minimum absolute lethal dose of OPCs is 1.3 LD50 (25).
The administration of atropine made it possible for rats to
survive the absolute lethal dose of paraoxon. That enabled
monitoring of signs of poisoning at high doses of paraoxon. As expected, atropine blocked to some extent the muscarinic effects, but not the nicotinic ones. Since different
doses of paraoxon were administered in rats treated with
saline or atropine, the results are not comparable. However, this makes it possible to compare the signs of poisoning
in future studies with other antidotes.
In clinical settings, mainly muscarinic signs of OPC
poisoning are expected. Bronchoconstriction and bronchorrhea are life-threatening muscarinic effects. Most studies have cited respiratory failure as the leading cause of
death (26–28). Dyspnoea was observed as a sign of poisoning in the present experiment. No clear relationship was
15
found between the intensity of dyspnoea and the dose of
paraoxon. However, in the recent study, a clear relationship was found between the onset rate of dyspnoea, as well
as the overall intensity of dyspnoea and lethal outcome
of poisoning (29). Respiratory failure is a consequence
of both peripheral and central cholinergic effects (30).
Therefore, it is very important to administer an antidote
that can cross the blood-brain barrier and prevent central
respiratory depression (31).
Another muscarinic sign of poisoning that was observed is lacrimation. It is a sign that is easily noticeable.
It is not a sign that directly implies whether the animal is
endangered or not, but it is a good indicator of excessive
muscarinic stimulation. In the treatment of OPC poisoning, the lack of lacrimation is one of the signs of achieving
the so-called patient atropinisation (5). The results of this
study also support this assumption. Although significantly
higher doses of paraoxon were administered, the lacrimation occurred significantly less frequently in rats treated
with atropine (22% vs 55%).
ACh is also found in the preganglionic nerve endings
of the sympathetic nervous system (32). Stimulation of
alpha-1-adrenergic receptors also leads to piloerection
(33). Therefore, piloerection can serve as an indirect indicator of sympathetic stimulation. The results of this study
showed a clear relationship between both the frequency
and intensity of piloerection and the dose of paraoxon. Besides, piloerection occurred more often and was of stronger intensity in non-survivors.
Tachycardia and hypertension are rarely expected in
patients with OPI intoxications and they often mislead
physicians in practice. Saadeh et al found tachycardia in
as many as 35–60% of patients poisoned by OPCs (34). It
means that tachycardia occurs more often than bradycardia, which indicates that it is a prejudice not to expect
nicotinic effects in OPC poisonings. Nicotinic signs of poisoning occur as a consequence of excessive stimulation of
ganglionic nicotinic receptors (hypertension, tachycardia, diaphoresis) as well as receptors at the neuromuscular junction (fibrillation and fasciculation) (35). In AChEI
poisoning, hypertension and tachycardia can also occur as
a consequence of excessive stimulation of the locus coeruleus. Stimulation of this cholinergically innervated sympathetic nuclei leads to the centrally-originated hypertension (36, 37).
As already mentioned, ACh is a neurotransmitter of
the peripheral nervous system, as well. Excessive stimulation of nicotinic receptors at the neuromuscular junction
leads to fasciculations, a toxic phenomenon observed in
this study. Fasciculations were the most consistent sign of
the severity of rat poisoning. They were more intense at
higher doses of paraoxon and in non-survivors throughout the observed period. This is in favour of the fact that
nicotinic signs of poisoning appear in severe poisonings
(38). When sarin was used in a terrorist attack in the
crowded subway in Tokyo, over 5,000 people were injured
and 12 people died (7, 39). Published reports cited nicotinic
signs of poisoning in severely poisoned patients (40, 41). In
rats treated with high doses of paraoxon and atropine, fasciculations were more common in survivors. This can be
explained by the rapid lethal outcome of poisoning, which
16
left non-survivors without this toxic sign. Fasciculations
often did not occur in the first 10 minutes of poisoning, but
were present even after 4 hours in all survivors. In other
words, it means that the non-survivors died too quickly to
develop fasciculations. Experimental studies with antinicotinic drugs showed their significant antidotal efficacy
against carbamates and OPCs (21). However, nicotinic receptor blockers are rarely used in clinical practice in the
treatment of OPC poisonings, due to serious side effects at
therapeutic doses of these drugs, primarily the respiratory
muscle depression (42).
Tremor is mediated by a variety of neurotransmitters –
dopamine, glutamate, serotonin, adenosine and acetylcholine (43). The M2 muscarinic receptors are highly expressed in the nucleus basalis and occipital cortex, then in
hippocampus and other cortical regions. Overstimulation
of M2 receptors leads to tremor (44). There is a conflicting evidence regarding the role of M3 and M4 receptors in
tremor aetiology (45). In this study, a clear relationship
was found between the intensity of poisoning, on the one
hand and the dose of paraoxon and the outcome of the
poisoning, on the other hand. In atropine-protected rats,
tremor occurred in all animals. Tremor is often found as
a part of the extrapyramidal syndrome that occurs as a
consequence of permanent CNS damage in OPC poisoning
survivors (21, 46, 47).
Stereotypical movements were registered more often
in survivors and at lower dose of paraoxon. The heavily
poisoned animals had significantly decreased spontaneous motor activity. Thus, the appearance of stereotypical
movements could be a good prognostic sign of a positive
outcome of poisoning. At the highest doses of paraoxon
(0.9 and 1.2 mg/kg), ataxia was more common in survivors. Atropine prevented the death of rats, but not the
skeletal muscle fatigue. As a consequence, only surviving
rats could attempt to move in the cage and these movements were ataxic.
Seizures intensity was directly related to the dose of
paraoxon and the lethal outcome of the poisoning. A total of 66.67% of survivors vs 100% of non-survivors had
seizures. Seizures occur at the beginning of OPC poisoning due to the excessive cholinergic stimulation of the
CNS. There are three treatment periods after the onset
of OPC-induced convulsions: muscarinic, gamma-aminobutyric acid A (GABAA)/benzodiazepine and glutamatergic ones (48). During the first one, antimuscarinic drugs
(atropine and, preferably, more lipophilic drugs, such as
scopolamine) can be efficiently used to stop the seizures,
provided the right dose is chosen (49). However, beyond
this period antimuscarinic drugs become ineffective in
counteracting the seizures, irrespective of the dose applied. In the second phase this could be compensated by
the administration of the GABAA/benzodiazepine receptor antagonists, such as barbiturates (e.g., pentobarbital,
thiopental sodium) and benzodiazepines (e.g., diazepam
or midazolam) (50, 51). In the third phase, these seizures
can be stopped by the administration of N-methyl-D-aspartate (NMDA) receptor antagonists, such as memantine,
dizocilpine (MK-801) or ketamine (52–55). The reason for
this is the fact that in the meanwhile the seizures became
glutamatergic in its origin (56). Along with fasciculations,
Žana M. Maksimović et al. Acta Medica (Hradec Králové)
seizures were the most constant sign of the severity of the
poisoning.
CONCLUSION
Among all the studied signs of paraoxon toxicity, the intensity of fasciculations and seizures were strong prognostic parameters of the severity of poisoning. They are
easily observed and are directly related to both the dose of
paraoxon and the lethal outcome of the poisoning. Based
on the relationship between the frequency and intensity
of muscarinic or nicotinic signs and the doses of paraoxon or outcomes of the poisoning, there are two strong
prognostic parameters of the severity of poisoning (fasciculations and seizures) and a good prognostic sign of a
positive outcome of poisoning (stereotypical movements).
These signs of poisoning may be useful to researchers in
monitoring the expected treatment outcome. Also, the
appearance of nicotinic and central signs of poisoning in
patients indicates the severity of poisoning and provides
guidance to clinicians on which potential therapy to use.
FUNDING
This study is partially funded by the Ministry of Scientific and Technological Development, Higher Education and
Informational Society of the Government of the Republic
of Srpska (Grant No 125 7030).
ABBREVIATIONS
ACh: acetylcholine; AChE: acetylcholinesterase; AChEI:
acetylcholinesterase inhibitor; OPC: organophosphorus
compounds; OPI: organophosphate insecticide
REFERENCES
1. Brown DA. Acetylcholine and cholinergic receptors. Brain Neurosci
Adv 2019 Mar 21; 3: 2398212818820506.
2. Pope CN, Brimijoin S. Cholinesterases and the fine line between poison and remedy. Biochem Pharmacol 2018 Jul; 153: 205–16.
3. Xiao C, Zhou CY, Jiang JH, Yin C. Neural circuits and nicotinic acetylcholine receptors mediate the cholinergic regulation of midbrain
dopaminergic neurons and nicotine dependence. Acta Pharmacol Sin
2020 Jan; 41(1): 1–9.
4. Vale A, Lotti M. Organophosphorus and carbamate insecticide poisoning. Handb Clin Neurol 2015; 131: 149–68.
5. Eddleston M. Novel clinical toxicology and pharmacology of organophosphorus insecticide self-poisoning. Annu Rev Pharmacol Toxicol
2019 Jan 6; 59: 341–60.
6. Henretig FM, Kirk MA, McKay CA Jr. Hazardous chemical emergencies and poisonings. N Engl J Med 2019 Apr 25; 380(17): 1638–55.
7. Stojiljković MP. Nerve agents – a clear and present danger to mankind. Scr Med 2019; 50(3): 109–11.
8. Lorke DE, Nurulain SM, Hasan MY, Kuča K, Petroianu GA. Combined
pre- and posttreatment of paraoxon exposure. Molecules 2020 Mar
27; 25(7): 1521.
9. Wadia RS, Sadagopan C, Amin RB, Sardesai HV. Neurological manifestations of organophosphate insecticide poisoning. J Neurol Neurosurg Psychiatry 1974 Jul; 37(7): 841–7.
10. Reddy BS, Skaria TG, Polepalli S, et al. Factors associated with outcomes in organophosphate and carbamate poisoning: a retrospective
study. Toxicol Res 2020 Feb 7; 36(3): 257–66.
Paraoxon Toxicity Signs Related to Dose and Outcome
11. Amend N, Niessen KV, Seeger T, Wille T, Worek F, Thiermann H. Diagnostics and treatment of nerve agent poisoning-current status and
future developments. Ann N Y Acad Sci 2020 Nov; 1479(1): 13–28.
12. National Research Council (US) Committee for the Update of the
Guide for the Care and Use of Laboratory Animals. Guide for the
Care and Use of Laboratory Animals. 8th edition. Washington (DC):
National Academies Press (US); 2011. Available from: https://www
.ncbi.nlm.nih.gov/books/NBK54050/.
13. Litchfield JT Jr, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949 Jun; 96(2): 99–113.
14. WHO. The WHO recommended classification of pesticides by hazard
2019. Geneva, 2019. (Accessed 2021-May-02 at https://apps.who
.int/iris/bitstream/handle/10665/332193/9789240005662-eng
.pdf?ua=1.)
15. Amir A, Raza A, Qureshi T, et al. Organophosphate poisoning: demographics, severity scores and outcomes from National Poisoning
Control Centre, Karachi. Cureus 2020 May 31; 12(5): e8371.
16. Kaushal J, Khatri M, Arya SK. A treatise on organophosphate pesticide pollution: Current strategies and advancements in their environmental degradation and elimination. Ecotoxicol Environ Saf 2020
Oct 22; 207: 111483.
17. WHO. Health topics: mental health. Geneva, 2004. (Accessed 2021May-02 at https://www.who.int/mental_health/prevention/suicide
/en/PesticidesHealth2.pdf.)
18. Misik J, Pavlikova R, Cabal J, Kuca K. Acute toxicity of some nerve
agents and pesticides in rats. Drug Chem Toxicol 2015 Jan; 38(1):
32–6.
19. Holmstedt B. Pharmacology of organophosphorus cholinesterase inhibitors. Pharmacol Rev 1959 Sep; 11: 567–688.
20. Parkes MW, Sacra P. Protection against the toxicity of cholinesterase
inhibitors by acetylcholine antagonists. Br J Pharmacol Chemother
1954 Sep; 9(3): 299–305.
21. Stojiljković MP, Škrbić R, Jokanović M, Kilibarda V, Bokonjić D, Vulović M. Efficacy of antidotes and their combinations in the treatment of acute carbamate poisoning in rats. Toxicology 2018 Sep 1;
408: 113–24.
22. Kords H, Lüllmann H, Ohnesorge FK, Wassermann O. Action of atropine and some hexane-1.6-bis-ammonium derivatives upon the
toxicity of DFP im mice. Eur J Pharmacol 1968 Jul; 3(4): 341–6.
23. Albuquerque EX, Pereira EF, Aracava Y, et al. Effective countermeasure against poisoning by organophosphorus insecticides and nerve
agents. Proc Natl Acad Sci U S A 2006 Aug 29; 103(35): 13220–5.
24. Krutak-Krol H, Domino EF. Comparative effects of diazepam and
midazolam on paraoxon toxicity in rats. Toxicol Appl Pharmacol
1985 Dec; 81(3 Pt 1): 545–50.
25. Antonijević B, Stojiljković MP, Bokonjić D, Vucinić S. [Antidotal effect
of combinations obidoxime/HI-6 and memantine in mice poisoned
with soman, dichlorvos or heptenophos]. Vojnosanit Pregl 2011 Dec;
68(12): 1033–40. Serbian.
26. Eddleston M, Eyer P, Worek F, et al. Differences bet organophosphorus insecticides in human self-poisoning: a prospective cohort study.
Lancet 2005 Oct 22–28; 366(9495): 1452–9.
27. Namba T, Nolte CT, Jackrel J, Grob D. Poisoning due to organophosphate insecticides. Acute and chronic manifestations. Am J Med
1971; 50(4): 475–92.
28. Ballantyne B, Marrs TC. Overview of the biological and clinical aspects of organophosphates and carbamates. In: Ballantyne B, Marrs
TC, eds. Clinical and experimental toxicology of organophosphates
and carbamates. Oxford: Butterworth-Heinemann; 1992, p. 3–14.
29. Maksimović ŽM, Duka D, Bednarčuk N, Škrbić R, Stojiljković MP.
Onset rate and intensity of signs of organophosphate poisoning related to paraoxon dose and survival in rats. Scr Med 2021 Mar; 52(1):
49–58.
30. Villa AF, Houze P, Monier C, et al. Toxic doses of paraoxon alter the
respiratory pattern without causing respiratory failure in rats. Toxicology 2007 Mar 22; 232(1–2): 37–49.
31. Houze P, Pronzola L, Kayouka M, Villa A, Debray M, Baud FJ. Ventilatory effects of low-dose paraoxon result from central muscarinic
effects. Toxicol Appl Pharmacol 2008 Dec 1; 233(2): 186–92.
32. Dhanarisi J, Shihana F, Harju K, et al. A pilot clinical study of the neuromuscular blocker rocuronium to reduce the duration of ventilation
after organophosphorus insecticide poisoning. Clin Toxicol (Phila)
2020 Apr; 58(4): 254–6.
17
33. Kikuchi-Utsumi K, Ishizaka M, Matsumura N, Nakaki T. Alpha(1A)-adrenergic control of piloerection and palpebral fissure
width in rats. Auton Neurosci 2013 Dec; 179(1–2): 148–50.
34. Saadeh AM, Farsakh NA, al-Ali MK. Cardiac manifestations of acute
carbamate and organophosphate poisoning. Heart 1997; 77(5):
461–4.
35. Turner SR, Chad JE, Price M, et al. Protection against nerve agent poisoning by a noncompetitive nicotinic antagonist. Toxicol Lett 2011
Sep 25; 206(1): 105–11.
36. Dirnhuber P, Cullumbine H. The effect of anti-cholinesterase angents
on the rat’s blood pressure. Br J Pharmacol Chemother 1955 Mar;
10(1): 12–5.
37. Varagić V. The action of eserine on the blood pressure of the rat. Br J
Pharmacol Chemother 1955 Sep; 10(3): 349–53.
38. Persson HE, Sjöberg GK, Haines JA, Pronczuk de Garbino J. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol
1998; 36(3): 205–13.
39. Yokoyama K, Yamada A, Mimura N. Clinical profiles of patients with
sarin poi¬soning after the Tokvo subway attack. Am J Med 1996 May:
100(5): 586.
40. Nozaki H, Aikawa N, Shinozawa Y, Hori S, Fujishima S, Takuma K, et
al. Sarin poisoning in Tokyo subway. Lancet 1995 Apr 15: 345(8955):
980–1.
41. Suzuki T, Morita H, Ono K, Maekawa K, Nagai R, Yazaki Y. Sarin poisoning in To¬kyo subway. Lancet 1995 Apr 15; 345(8955): 980.
42. Sheridan RD, Smith AP, Turner SR, Tattersall JE. Nicotinic antagonists in the treatment of nerve agent intoxication. J R Soc Med 2005
Mar; 98(3): 114–5.
43. Collins LE, Galtieri DJ, Brennum LT, et al. Oral tremor induced by the
muscarinic agonist pilocarpine is suppressed by the adenosine A2A
antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX. Pharmacol Biochem Behav 2010 Feb; 94(4): 561–9.
44. Gomeza J, Shannon H, Kostenis E, et al. Pronounced pharmacologic
deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc
Natl Acad Sci U S A 1999 Feb 16; 96(4): 1692–7.
45. Scarr E. Muscarinic receptors: their roles in disorders of the central
nervous system and potential as therapeutic targets. CNS Neurosci
Ther 2012 May; 18(5): 369–79.
46. Jokanović M. Neurotoxic effects of organophosphorus pesticides and
possible association with neurodegenerative diseases in man: A review. Toxicology 2018 Dec 1; 410: 125–31.
47. Reji KK, Mathew V, Zachariah A, et al. Extrapyramidal effects of
acute organophosphate poisoning. Clin Toxicol (Phila) 2016 Mar;
54(3): 259–65.
48. Stojiljković MP, Jokanović M, Lončar-Stojiljković D, Škrbić R. Prophylactic and therapeutic measures in nerve agents poisonings. In:
Gupta RC. Handbook of toxicology of chemical warfare agents. 3rd
ed. Cambridge, MA, USA: Academic Press; 2020, p. 1145–1159.
49. Myhrer T, Nguyen NH, Andersen JM, Aas P. Protection against soman-induced seizures in rats: relationship among doses of prophylactics, soman, and adjuncts. Toxicol Appl Pharmacol 2004 May 1;
196(3): 327–36.
50. Shih T, McDonough JH Jr, Koplovitz I. Anticonvulsants for soman-induced seizure activity. J Biomed Sci 1999 Mar–Apr; 6(2): 86–96.
51. Bokonjić D, Rosić N. Anticonvulsive and protective effects of diazepam and midazolam in rats poisoned by highly toxic organophosphorus compounds. Arh Hig Rada Toksikol 1991 Dec; 42(4): 359–65.
52. Spampanato J, Bealer SL, Smolik M, Dudek FE. Delayed adjunctive
treatment of organophosphate-induced status epilepticus in rats
with phenobarbital, memantine, or dexmedetomidine. J Pharmacol
Exp Ther 2020 Oct; 375(1): 59–68.
53. Stojiljković MP, Škrbić R, Jokanović M, Bokonjić D, Kilibarda V, Vulović M. Prophylactic potential of memantine against soman poisoning in rats. Toxicology 2019 Mar 15; 416: 62–74.
54. Weissman BA, Raveh L. Therapy against organophosphate poisoning: the importance of anticholinergic drugs with antiglutamatergic
properties. Toxicol Appl Pharmacol 2008 Oct 15; 232(2): 351–8.
55. Stojiljković MP, Škrbić R, Jokanović M, Kilibarda V, Bokonjić DR,
Maksimović M. Effects of memantine and its metabolite Mrz 2/373
on soman-induced inhibition of acetylcholinesterase in vitro. Chem
Biol Interact 2021 Jun 1; 342: 109463.
56. Rusyniak DE, Nañagas KA. Organophosphate poisoning. Semin Neurol 2004 Jun; 24(2): 197–204.